Compare CMT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMT | ARMP |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | 1239 | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 199.7M |
| IPO Year | 1996 | 1996 |
| Metric | CMT | ARMP |
|---|---|---|
| Price | $23.89 | $5.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $24.00 | $15.00 |
| AVG Volume (30 Days) | 19.5K | ★ 98.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $284,290,000.00 | N/A |
| Revenue This Year | $4.58 | N/A |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $89.48 | ★ N/A |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $16.60 | $2.76 |
| 52 Week High | $28.69 | $14.98 |
| Indicator | CMT | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 53.08 |
| Support Level | $22.80 | $5.12 |
| Resistance Level | $25.38 | $5.63 |
| Average True Range (ATR) | 1.10 | 0.47 |
| MACD | -0.22 | 0.08 |
| Stochastic Oscillator | 26.38 | 76.58 |
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.